CG Oncology Reports Third-Quarter 2026 Financial Results and Business Updates
CG Oncology reported results for the quarter ended September 30, 2026. The company said it expects to share PIVOT-006 topline data this month.
Story updates
01:16:49 PM UTC
SquawkNews
CG Oncology reported third-quarter 2026 financial results and expects PIVOT-006 topline data this month. It also expects 12-month data from CORE-008 Cohort CX and BOND-003 Cohort P in December; financial figures were not provided in the release text.Material DetailsContext by AI AnalystThe company…
01:33:26 PM UTC
SquawkNews
CG Oncology reported third-quarter 2026 revenue of $1.6 million and a net loss of $56.9 million, or $0.64 per share. Cash, cash equivalents and marketable securities totaled $984.5 million at September 30, which the company expects to fund operations through 2029. The company anticipates several cl…
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. NASDAQ:CGON today reported financial results for the third quarter ended September 30, 2026, and provided business updates.“We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month…